| Schedule of Information by Segment of the Operations for the Year Ended |
The following table presents summarized information by segment of the operations for the six months ended June 30, 2026: | | | Internet hospital | | | Pharmaceutical supply chain | | | Total | | | | | RMB | | | RMB | | | RMB | | | Net revenue | | | 100,256,709 | | | | 84,743,550 | | | | 185,000,259 | | | Less: | | | | | | | | | | | | | | Cost of revenues | | | (76,291,840 | ) | | | (83,434,892 | ) | | | (159,726,732 | ) | | Salaries and welfare | | | (12,539,740 | ) | | | (1,568,527 | ) | | | (14,108,267 | ) | | Commissions to doctors | | | (14,958,350 | ) | | | — | | | | (14,958,350 | ) | | Consultancy and professional service fees | | | (4,720,112 | ) | | | (2,970 | ) | | | (4,723,082 | ) | | Advertising and promotion costs | | | (1,416,450 | ) | | | (307,006 | ) | | | (1,723,456 | ) | | Contracted development and research service fees | | | (104,460,801 | ) | | | — | | | | (104,460,801 | ) | | Other segment items* | | | (5,482,449 | ) | | | (820,806 | ) | | | (6,303,255 | ) | | Segment loss | | | (119,613,033 | ) | | | (1,390,651 | ) | | | (121,003,684 | ) | | | | | | | | | | | | | | | | Reconciliation of segment loss: | | | | | | | | | | | | | | Impairment on long-lived assets and long-term assets | | | | | | | | | | | (456,520 | ) | | Other professional service fees | | | | | | | | | | | (111,872,922 | ) | | Other income | | | | | | | | | | | 1,333,963 | | | Other expense | | | | | | | | | | | (59,121 | ) | | Interest expense | | | | | | | | | | | (6,121,392 | ) | | Government grants | | | | | | | | | | | 76,619 | | | Loss before income tax | | | | | | | | | | | (238,103,057 | ) | | | | Internet hospital | | | Pharmaceutical supply chain | | | Total | | | | | US$ | | | US$ | | | US$ | | | Net revenue | | | 14,776,010 | | | | 12,489,654 | | | | 27,265,664 | | | Less: | | | | | | | | | | | | | | Cost of revenues | | | (11,244,026 | ) | | | (12,296,781 | ) | | | (23,540,807 | ) | | Salaries and welfare | | | (1,848,129 | ) | | | (231,172 | ) | | | (2,079,301 | ) | | Commissions to doctors | | | (2,204,588 | ) | | | — | | | | (2,204,588 | ) | | Consultancy and professional service fees | | | (695,658 | ) | | | (438 | ) | | | (696,096 | ) | | Advertising and promotion costs | | | (208,759 | ) | | | (45,247 | ) | | | (254,006 | ) | | Contracted development and research service fees | | | (15,395,617 | ) | | | — | | | | (15,395,617 | ) | | Other segment items* | | | (808,012 | ) | | | (120,972 | ) | | | (928,984 | ) | | Segment loss | | | (17,628,779 | ) | | | (204,956 | ) | | | (17,833,735 | ) | | | | | | | | | | | | | | | | Reconciliation of segment loss: | | | | | | | | | | | | | | Impairment on long-lived assets and long-term assets | | | | | | | | | | | (67,282 | ) | | Other professional service fees | | | | | | | | | | | (16,488,029 | ) | | Other income | | | | | | | | | | | 196,601 | | | Other expense | | | | | | | | | | | (8,713 | ) | | Interest expense | | | | | | | | | | | (902,182 | ) | | Government grants | | | | | | | | | | | 11,292 | | | Loss before income tax | | | | | | | | | | | (35,092,048 | ) | | * | For each reportable segment, the other segment item category primarily includes shipping expenses, rental costs, entertainment expense, office expense and expected credit losses. | The following table presents summarized information by segment of the operations for the six months ended June 30, 2025: | | | Internet hospital | | | Pharmaceutical supply chain | | | Total | | | | | RMB | | | RMB | | | RMB | | | Net revenue | | | 67,161,426 | | | | 107,308,425 | | | | 174,469,851 | | | Less: | | | | | | | | | | | | | | Cost of revenues | | | (39,984,734 | ) | | | (106,167,716 | ) | | | (146,152,450 | ) | | Salaries and welfare | | | (10,611,116 | ) | | | (1,261,093 | ) | | | (11,872,209 | ) | | Commissions to doctors | | | (12,590,966 | ) | | | — | | | | (12,590,966 | ) | | Consultancy and professional service fees | | | (6,447,195 | ) | | | — | | | | (6,447,195 | ) | | Advertising and promotion costs | | | (2,406,666 | ) | | | (1,269,934 | ) | | | (3,676,600 | ) | | Other segment items* | | | (4,344,401 | ) | | | (804,761 | ) | | | (5,149,162 | ) | | Segment loss | | | (9,223,652 | ) | | | (2,195,079 | ) | | | (11,418,731 | ) | | | | | | | | | | | | | | | | Reconciliation of segment loss: | | | | | | | | | | | | | | Impairment on long-lived assets and long-term assets | | | | | | | | | | | (2,041,299 | ) | | Other income | | | | | | | | | | | 28,027 | | | Other expense | | | | | | | | | | | (130,291 | ) | | Interest expense | | | | | | | | | | | (6,471,198 | ) | | Government grants | | | | | | | | | | | 148,000 | | | Loss before income tax | | | | | | | | | | | (19,885,492 | ) | | * | For each reportable segment, the other segment item category primarily includes shipping expenses, rental costs, entertainment expense, office expense and expected credit losses. |
|
| Schedule of Net Revenue from External Customers |
In accordance with the enterprise-wide disclosure requirements, the Group’s net revenue from external customers through Internet hospital by main product category is as follows: | | | For the Six Months Ended June 30, | | | | | 2025 | | | 2026 | | | 2026 | | | | | RMB | | | RMB | | | US$ | | | Prescription drugs | | | 65,961,298 | | | | 98,081,651 | | | | 14,455,447 | | | Over-the-counter (“OTC”) medicines | | | 448,733 | | | | 634,209 | | | | 93,471 | | | Traditional Chinese medicine (“TCM”) | | | 5,812 | | | | 63,063 | | | | 9,294 | | | Medical apparatus and instruments (“MAAI”) | | | 9,735 | | | | 20,444 | | | | 3,013 | | | Online consultation | | | 714,205 | | | | 789,437 | | | | 116,349 | | | Others | | | 21,643 | | | | 667,905 | | | | 98,436 | | | Total | | | 67,161,426 | | | | 100,256,709 | | | | 14,776,010 | | The Group’s net revenue from external customers through pharmaceutical supply chain by main product category is as follows: | | | For the Six Months Ended June 30, | | | | | 2025 | | | 2026 | | | 2026 | | | | | RMB | | | RMB | | | US$ | | | Prescription drugs | | | 81,105,612 | | | | 12,482,803 | | | | 1,839,738 | | | Over-the-counter (“OTC”) medicines | | | 24,792,741 | | | | 2,079,288 | | | | 306,449 | | | Traditional Chinese medicine (“TCM”) | | | (1,676,538 | ) | | | 25,527 | | | | 3,762 | | | Medical apparatus and instruments (“MAAI”) | | | 39,273 | | | | 69,042,976 | | | | 10,175,676 | | | Others | | | 3,047,337 | | | | 1,112,956 | | | | 164,029 | | | Total | | | 107,308,425 | | | | 84,743,550 | | | | 12,489,654 | |
|